We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,035

Are Drug Prices Really Too High?
  • Foley & Lardner LLP
  • USA
  • May 5 2016

Those working in the pharmaceutical space are used to hearing complaints about the high costs of drugs, and patents often are blamed for allowing


District Court Applies Mayo To Treatment Claims But Denies Motion To Dismiss BMS Keytruda Litigation
  • Foley & Lardner LLP
  • USA
  • May 3 2016

The U.S. District Court for the District of Delaware accepted Merck's arguments that method of treatment patents asserted by BMS against its Keytruda


Having A Bad Hair Day? The Federal Circuit Agrees That Method Of Cutting Hair Is Invalid Under 101
  • Foley & Lardner LLP
  • USA
  • April 28 2016

While I do not usually write about non-precedential decisions, In re: Brown caught my eye as an interesting patent eligibility case. It does not


Reading The Cuozzo Tea Leaves: Best Practices Pending The Supreme Court's Decision
  • Foley & Lardner LLP
  • USA
  • April 27 2016

The Supreme Court of the United States heard oral argument today on claim construction in inter parte review (IPR) proceedings and the reviewability


Will The Celsis Appeal Put An End To 101 Rejections Of Laboratory Method Claims?
  • Foley & Lardner LLP
  • USA
  • April 26 2016

On April 5, 2016, the Federal Circuit heard oral arguments in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., where the U.S. District Court for the


Amneal's IPR Challenge Of The Jazz Xyrem Valproate Patent
  • Foley & Lardner LLP
  • USA
  • April 21 2016

In decisions dated April 12, 2016, the USPTO Patent Trial and Appeal Board (PTAB) denied institution as to claims 1-18 of Jazz's U.S. Patent 8,772


Can Foreign Sales Infringe U.S. Patents?
  • Foley & Lardner LLP
  • USA
  • April 21 2016

It is a deceptively simple question with a not so simple answer. A purely foreign transaction is certainly beyond the reach of U.S. patent law, but


Jazz Xyrem Valproate Patent Claims Avoid IPR
  • Foley & Lardner LLP
  • USA
  • April 18 2016

The USPTO Patent Trial and Appeal Board (PTAB) decided not to institute inter partes review (IPR) of key claims of Jazz's U.S. Patent 8,772,306


Court Can't Review Policy Behind Patent Term Adjustment Statute
  • Foley & Lardner LLP
  • USA
  • April 14 2016

In Singhal v. Lee, the U.S. District Court for the Eastern District of Virginia dismissed a complaint that challenged the Patent Term Adjustment


Methods Exploiting Junk DNA May Be Useful But Lack Patent Eligibility
  • Foley & Lardner LLP
  • USA
  • April 11 2016

Striking another blow against patent eligibility in the field of biotechnology, the Federal Circuit agreed with the district court that methods that